Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKSO trial of aprepitant versus ondansetron for prevention of postoperative nausea and vomiting after minimally invasive lung wedge resection
ChiCTR2300075028Phase 4Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Aprepitant group with Ondansetron group (2 arms). Primary endpoint: Complete remission rate within 24 hours postoperatively. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
aprepitantondansetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2300075028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075028.